Stavros Touloupidis

Stavros Touloupidis

Auto-generated profile, based on publicly available information

Stavros Touloupidis

Departments of Urology, University of Thrace, Alexandroupolis, Greece

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
CACharalampos Andreadis
Charalampos Andreadis
STStavros Touloupidis
Stavros Touloupidis
GGGrammati Galaktidou
Grammati Galaktidou
AKAlexandros H. Kortsaris
Alexandros H. Kortsaris
ABAnastasios Boutis
Anastasios Boutis
DMDespina Mouratidou
Despina Mouratidou
Previous studies have shown that serum levels of the degradation products of cytokeratins could be used as surrogate markers in the diagnosis and followup of patients with solid tumors, including tumors of the bladder. The soluble cytokeratin 19 fragment CYFRA 21–1 was measured by solid phase radioimmunoassay in the serum of 142 patients with invasive transitional cell cancer of the bladder. Of the patients 56 had clinical stage I to III locally confined disease (T1–4aN0M0) and 86 had stage IV metastatic disease with lymph node and/or distant metastases. A control group consisted of 33 healthy volunteers. In a subgroup of 49 patients with metastatic disease receiving combined platinum based chemotherapy serum CYFRA 21–1 was determined prior to the initiation of therapy and after the documentation of response. Abnormal CYFRA 21–1 was observed in 7% of patients with locally invasive disease and in 66% of those with metastatic disease (p <0.0001). There was no correlation of CYFRA 21–1 with tumor differentiation. Patients with abnormal CYFRA 21–1 showed statistically significant worse median overall survival. Moreover, in the subgroup of patients with metastatic disease receiving chemotherapy CYFRA 21–1 levels correlated with the response to treatment. Patients with transitional cell cancer of the bladder with evidence of distant metastases showed a significant increase in serum CYFRA 21–1. During chemotherapy CYFRA 21–1 appears to be a potentially sensitive and useful indicator for monitoring treatment response.

23 November 2006 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
STStavros Touloupidis
Stavros Touloupidis
CKChristos Kalaitzis
Christos Kalaitzis
ASAndreas Schneider
Andreas Schneider
EPEmmanuel Patris
Emmanuel Patris
AKAnastasios Kolias
Anastasios Kolias

1 March 2006 in Asian Journal of Andrology
Verified
Journal Article
Open access
FPFotini Papachristou
Fotini Papachristou
TLTheodore Lialiaris
Theodore Lialiaris
STStavros Touloupidis
Stavros Touloupidis
CKChristos Kalaitzis
Christos Kalaitzis
CSConstantinos Simopoulos
Constantinos Simopoulos
NSNikolaos Sofikitis
Nikolaos Sofikitis
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.

1 December 2002 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
RVRombis Vasileios
Rombis Vasileios
PAPapathanasiou Athanasios
Papathanasiou Athanasios
TSTouloupidis Stavros
Touloupidis Stavros

1 June 2006 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
STStavros Touloupidis
Stavros Touloupidis
APAthanasios Papathanasiou
Athanasios Papathanasiou
CKChristos Kalaitzis
Christos Kalaitzis
GFGeorgios Fatles
Georgios Fatles
IMIoannis Manavis
Ioannis Manavis
VRVassilios Rombis
Vassilios Rombis

1 January 2004 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
SGStefanos Gardikis
Stefanos Gardikis
CSChrissostomos Soultanidis
Chrissostomos Soultanidis
SDSavas Deftereos
Savas Deftereos
KKKaterina Kambouri
Katerina Kambouri
CVChristoshimas George Vaos
Christoshimas George Vaos
CSConstantinos Simopoulos
Constantinos Simopoulos